Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 8Terminated 3Unknown 2Recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 83Thoracic 58Gynecologic 46Gastrointestinal 39Head & Neck 21Genitourinary 10Tumor-Agnostic 6Dermatologic 6Sarcoma 4Other solid neoplasm 4CNS 3Endocrine 2Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Thyroid Carcinoma, Anaplastic 2Thyroid Neoplasms 1

Interventions

lutetium Lu 177 dotatate 14Nivolumab 12Magnetic Resonance Spectroscopy 11pembrolizumab 10Specimen Handling 10Ipilimumab 9cabozantinib 8trametinib 6lenvatinib 6Temozolomide 6dabrafenib 4atezolizumab 4Lutetium-177 4Immunoglobulin G 4Everolimus 4Disulfides 4CTLA-4 Antigen 4selpercatinib 3Octreotide 3Cisplatin 3Carboplatin 3Capecitabine 3Bevacizumab 3entrectinib 2copper dotatate CU-64 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Vemurafenib 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Paclitaxel × Endocrine × Clear all
NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
50 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03085056 2025-07-03

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
13 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡